Equities analysts expect Novavax, Inc. (NASDAQ:NVAX) to report ($2.65) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Novavax’s earnings. The highest EPS estimate is ($1.02) and the lowest is ($3.74). Novavax reported earnings of ($0.58) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 356.9%. The firm is expected to issue its next earnings results on Monday, May 10th.
On average, analysts expect that Novavax will report full-year earnings of $25.35 per share for the current year, with EPS estimates ranging from $20.81 to $27.32. For the next fiscal year, analysts anticipate that the company will report earnings of $32.84 per share, with EPS estimates ranging from $16.27 to $44.18. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Novavax.
Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Monday, March 1st. The biopharmaceutical company reported ($2.70) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.53) by ($1.17). The business had revenue of $279.66 million during the quarter, compared to analysts’ expectations of $202.44 million. Novavax had a negative net margin of 133.10% and a negative return on equity of 1,346.17%. Novavax’s revenue for the quarter was up 3072.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.13) EPS.
Novavax stock traded up $6.66 during midday trading on Friday, reaching $178.43. The stock had a trading volume of 73,023 shares, compared to its average volume of 4,294,041. Novavax has a twelve month low of $16.30 and a twelve month high of $331.68. The stock has a market capitalization of $13.18 billion, a PE ratio of -33.80 and a beta of 2.01. The company has a debt-to-equity ratio of 3.61, a quick ratio of 2.81 and a current ratio of 2.81. The stock’s 50-day simple moving average is $209.29 and its 200 day simple moving average is $150.54.
In related news, EVP John Trizzino sold 191 shares of the business’s stock in a transaction dated Wednesday, April 7th. The stock was sold at an average price of $178.03, for a total value of $34,003.73. Following the completion of the sale, the executive vice president now directly owns 704 shares of the company’s stock, valued at $125,333.12. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Gregory M. Glenn sold 2,434 shares of the business’s stock in a transaction dated Thursday, February 18th. The shares were sold at an average price of $269.57, for a total value of $656,133.38. In the last quarter, insiders sold 64,497 shares of company stock worth $13,928,932. Insiders own 3.30% of the company’s stock.
Large investors have recently bought and sold shares of the company. Front Row Advisors LLC bought a new position in shares of Novavax during the third quarter valued at approximately $25,000. Carroll Financial Associates Inc. bought a new position in shares of Novavax during the first quarter valued at approximately $27,000. Sittner & Nelson LLC bought a new position in shares of Novavax during the fourth quarter valued at approximately $28,000. IFP Advisors Inc grew its holdings in shares of Novavax by 39.4% during the fourth quarter. IFP Advisors Inc now owns 336 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 95 shares during the last quarter. Finally, Neo Ivy Capital Management grew its holdings in shares of Novavax by 17,850.0% during the fourth quarter. Neo Ivy Capital Management now owns 359 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 357 shares during the last quarter. 49.91% of the stock is owned by institutional investors.
Novavax Company Profile
Novavax, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.
Featured Article: The role of implied volatility with call option volume
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.